Abiopharma

Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025

embecta Announces Quarterly Cash Dividend

Corporate Presentation 1h2025

General Announcement: Corporate Presentation 1H2025

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

FDA approve LAMOTRIGINE

FDA approve FUROSEMIDE

FDA approve IBANDRONATE SODIUM

FDA approve PEMETREXED DISODIUM

FDA approve TIGECYCLINE

FDA approve ROPIVACAINE HYDROCHLORIDE

FDA approve ICOSAPENT ETHYL

HOOKIPA Pharma Inc. (HOOK) was removed from the list of traded instruments on NASDAQ exchange

FDA approve ESLICARBAZEPINE ACETATE

FDA approve POMALIDOMIDE